Description: ISRG leverages refurbished Xi systems to reach cost-sensitive markets and expand access beyond hospitals.

Description: The Hip Replacement industry is poised for substantial growth, projected to reach US$ 10.24 billion by 2033, up from US$ 6.92 billion in 2024, at a CAGR of 4.45% between 2025 and 2033. This expansion is driven by increased awareness of procedures such as hip arthroplasty, which helps alleviate discomfort and enhance mobility for those with severe joint disorders. Factors such as rising obesity, orthopedic issues, and demand for surgical treatments contribute to market growth. Key players driving

Description: The viscosupplementation market is projected to grow robustly, reaching US$ 10.16 billion by 2033 from US$ 4.66 billion in 2024, with a CAGR of 9.02% from 2025 to 2033. This minimally invasive treatment involves injecting hyaluronic acid derivatives into knee joints to alleviate osteoarthritis symptoms such as inflammation and pain while enhancing joint mobility. Major companies like Smith & Nephew, Roche, Sanofi, Chugai Pharmaceuticals, and others play a pivotal role in this expanding industry.

Description: Zimmer Biomet Holdings has seen its consensus analyst price target decrease slightly from $104.84 to $102.92, reflecting a cautious reassessment among market watchers. While updated product launches and strategic moves such as the FNA acquisition inspire long-term optimism, recent quarterly results have prompted analysts to temper their near-term outlook. Stay with us to learn how these evolving expectations could shape the narrative for Zimmer Biomet going forward and discover ways to track...

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to

Description: Knee replacement surgery effectively addresses severe knee conditions like osteoarthritis, offering pain relief and improved mobility. The procedure sees high demand due to rising osteoarthritis among the aging population, especially as global lifespans increase. Although the surgery significantly enhances life quality, challenges such as high costs and lengthy recovery persist, affecting both patients and healthcare systems. The competitive market witnesses innovation from key players like Stry

Description: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Description: Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of ROSA® Knee with OptimiZe™, an enhanced version of its ROSA® Knee System that offers a more customized experience for surgeons to help deliver accurate and reproducible outcomes1 in robotic-assisted total knee replacement surgery.

Description: Investors were disappointed with the weak earnings posted by Zimmer Biomet Holdings, Inc. ( NYSE:ZBH ). While the...

Description: The regenerative medicine market offers significant opportunities in personalized stem cell therapies, driven by rising cancer cases and demand for effective chronic disease treatments. Emerging economies show potential for growth, propelled by an increasing need for tissue engineering and organ transplantation solutions. Regenerative Medicine Market Regenerative Medicine Market Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The "Regenerative Medicine Market - Global Industry Size, Share, Trends, Opp

Description: Canaccord lowered the firm’s price target on Zimmer Biomet (ZBH) to $93 from $101 and keeps a Hold rating on the shares. The firm updated its model following Q3 results and subsequent 10Q release. They noted the company tightened its guidance and reiterated reported growth of 6.7-7.7% with the FNA acquisition expected to contribute roughly 270bps to growth. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommend

Description: The Sports Medicine industry is projected to grow significantly, reaching US$ 12.32 Billion by 2033 from US$ 7.27 Billion in 2024, marking a CAGR of 6.04%. This growth is driven by increased sports participation, a focus on injury prevention, and advancements in sports medicine technology like minimally invasive surgical tools. Companies such as Temple Ortho Biologics are pioneering solutions for young athletes. Leading market players include Zimmer Biomet, Medtronic, and Stryker, emphasizing in

Description: Zimmer Biomet Holdings recently reported mixed third-quarter 2025 results, with US$2,001.4 million in sales and US$230.9 million in net income, alongside revised guidance lowering full-year organic revenue growth expectations due to ongoing challenges in international markets. At the same time, the company has taken steps forward in product innovation, gaining FDA Breakthrough Device Designation for its iodine-treated total hip replacement system and acquiring Monogram Technologies to expand...

Description: Zimmer Biomet Holdings has seen its Fair Value Estimate decrease from $110.92 to $104.84, reflecting a modest reassessment of the company's intrinsic value by analysts. This shift follows the latest earnings report, which highlighted both ongoing innovations and tempered growth expectations. Stay tuned to learn how you can stay informed about further shifts in the company's evolving investment story. Analyst Price Targets don't always capture the full story. Head over to our Company Report to...

Description: It's been a mediocre week for Zimmer Biomet Holdings, Inc. ( NYSE:ZBH ) shareholders, with the stock dropping 12% to...

Description: Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will be presenting at the Annual Jefferies Global Healthcare Conference in London on Tuesday, Nov. 18, 2025, at Noon GMT (7 a.m. ET).

Description: Henkell Freixenet was honored with the Ponce de León Company of the Year Award, while Iván Tornos, Chairman, President & CEO of Zimmer Biomet Holdings, Inc. (S&P 500), received the Ponce de León Corporate Leader of the Year Award. ...

Description: We recently published 10 Stocks Left Behind Amid Wall Street Cheer. Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is one of the worst-performing stocks on Wednesday. Zimmer dropped its share prices by 15.15 percent on Wednesday to end at $87.55 apiece as investors soured on its organic sales growth forecast amid weakness in international markets, alongside a […]

Description: Reports Q3 revenue $2B, consensus $2.01B. “Our third quarter performance was anchored by 5.6% organic revenue growth in our critical U.S. business, driven by accelerated adoption of our key new products referred to as the ‘Magnificent Seven,'” said Ivan Tornos, Chairman, President and CEO of Zimmer Biomet (ZBH). “This is highly encouraging, especially as we prepare to launch a second round of new-to-the-world technologies, including the first fully autonomous robot in orthopedics and our iodine

Description: Zimmer Biomet Holdings (ZBH) reported net profit margins of 10.5% for the most recent twelve months through September 2025, down from 13.3% a year ago. The period was impacted by a one-off loss of $304.6 million, with a negative turn in annual earnings growth despite an average rate of 26.4% over the past five years. Forward guidance puts EPS growth at 14.2% per year and revenue growth at 4.2% per year, both tracking behind the market. Shares continue to trade below fair value estimates and...

Description: The Nasdaq Composite rose Wednesday as technology stocks rebounded following a rout in the previous

Description: Zimmer Biomet Holdings Inc (ZBH) reports robust US sales and strategic advancements, while addressing international market challenges and revising growth expectations.

Description: Zimmer Biomet, the maker of knee and hip replacements, missed on quarterly sales estimates and lowered the top end of its outlook for full-year organic revenue growth.

Description: US benchmark equity indexes were higher intraday as traders parsed the latest economic data, includi

Description: Zimmer Biomet's Q3 EPS beats expectations, but a revenue miss and trimmed outlook send shares sliding in pre-market trading.

Description: Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Description: POMPANO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Curonix LLC (“Curonix” or the “Company”), a medical technology company dedicated to developing and commercializing innovative therapies to relieve chronic pain, today announced the appointment of Russell Fleeger as Chief Financial Officer, effective immediately. Bringing more than 25 years of global finance experience, including two decades in the medical device industry, Fleeger joins Curonix to help lead the Company into its next phase of

Description: Zimmer (ZBH) delivered earnings and revenue surprises of +1.06% and -0.42%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: CEO Ivan Tornos said multiple factors emerged late in the quarter that caused the shortfall. Zimmer’s shares plunged more than 15%.

Description: Medical device company Zimmer Biomet (NYSE:ZBH) met Wall Streets revenue expectations in Q3 CY2025, with sales up 9.7% year on year to $2.00 billion. Its non-GAAP profit of $1.90 per share was 2.1% above analysts’ consensus estimates.

Description: ZBH) on Wednesday reported third-quarter profit of $230.9 million. The Warsaw, Indiana-based company said it had profit of $1.16 per share. Earnings, adjusted for one-time gains and costs, were $1.90 per share.

Description: Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2025. The Company reported third quarter net sales of $2.001 billion, an increase of 9.7% over the prior year period, an increase of 8.6% on a constant currency1 basis and an increase of 5.0% on an organic constant currency1 basis. Net earnings for the third quarter were $230.9 million, or $377.0 million on an adjusted1 basis.

Description: Zimmer Biomet Holdings (ZBH) shares have seen steady movement lately, catching the interest of investors who track performance and valuation shifts. Recent stock action suggests a re-evaluation of expectations surrounding the company’s growth and profitability in the period ahead. See our latest analysis for Zimmer Biomet Holdings. Zimmer Biomet’s share price has picked up over the past three months, returning 13.2 percent and hinting at renewed optimism around the company’s growth outlook,...

Description: Medical device company Zimmer Biomet (NYSE:ZBH) will be reporting results this Wednesday morning. Here’s what to expect.

Description: Mexican Dental Implant Market Mexican Dental Implant Market Dublin, Oct. 29, 2025 (GLOBE NEWSWIRE) -- The "Mexico Dental Implant Market Forecast & Trends 2025-2033" has been added to ResearchAndMarkets.com's offering. The Mexico Dental Implant Market is expected to reach US$ 161.02 million in 2033, from US$ 87.88 million in 2024, at a CAGR of 6.96% during the years 2025-2033. This market is expected to be pushed by growing dental tourism, rising incidence of oral diseases, growing geriatric popu

Description: Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company's first-to-world iodine-treated total hip replacement system. This is the first product in Zimmer Biomet history to receive this designation.

Description: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Description: GE HealthCare's Q3 results are expected to show steady growth from Imaging and Diagnostics, though tariffs may weigh on margins and EPS.

Description: Earlier this week, Zimmer Biomet Holdings showcased its latest orthopedic robotics and digital health innovations, including FDA-cleared mBos TKA System and the recently acquired Monogram Technologies robotic platform, at the annual meeting of the American Association of Hip and Knee Surgeons. A standout revelation was the integration of AI-driven and autonomous technologies into the company's expanding knee and hip portfolios, reflecting Zimmer Biomet’s commitment to advancing surgical...

Description: Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped returns as the industry’s six-month gain of 13.5% has lagged the S&P 500’s 22.9% climb.

Description: Zimmer (ZBH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Description: ELV beats EPS estimates by 21% in Q3 as strong Medicare Advantage membership gains and Carelon revenue growth offset Medicaid losses.

Description: Dublin, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The "Zimmer Biomet Holdings Inc (ZBH) - Product Pipeline Analysis, 2025 Update" has been added to ResearchAndMarkets.com's offering. This comprehensive report serves as an essential source of data, analysis, and actionable intelligence regarding Zimmer Biomet's extensive portfolio of pipeline products. Detailed insights into the company's operations, major products, and brands are accompanied by analyses designed to enhance decision-making capabilities a

Description: Intuitive Surgical's new da Vinci 5 is driving strong hospital upgrades and premium pricing, setting up ISRG for potential top-line momentum in Q3.

Description: ZBH's Q3 results on Nov. 5 may show solid gains, driven by hip, knee, and S.E.T. segment growth and recent product approvals.

Description: Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it is highlighting bold innovations across its broad robotics and musculoskeletal portfolio at the 2025 annual meeting of the American Association of Hip and Knee Surgeons (AAHKS).

Description: Zimmer Biomet Holdings (ZBH) shares have made steady progress in recent weeks, with the stock climbing 8% over the past month. Investors seem to be weighing the company's fundamentals as it navigates a shifting healthcare landscape. See our latest analysis for Zimmer Biomet Holdings. Zimmer Biomet’s recent 8% weekly share price rally follows a period of steady long-term performance, though its 1-year total shareholder return remains slightly negative at -1.4%. This suggests that investors are...

Description: Zimmer Biomet Holdings Inc. (NYSE:ZBH) ranks among the best medical device stocks to invest in. Zimmer Biomet Holdings Inc. (NYSE:ZBH) announced on October 7 that it successfully acquired Monogram Technologies Inc., an AI-driven orthopedic robotics firm, for an upfront payment of about $177 million. This expands Zimmer Biomet’s orthopedic solution range by integrating Monogram’s semi-autonomous […]